Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to determine the safety profile and tolerability of S 55746 in patients with CLL, B-Cell NHL and MM, in terms of Dose-Limiting Toxicities (DLTs), Maximum Tolerated Dose (MTD) and determine the Recommended Phase 2 Dose (RP2D) through safety profile (DLT, MTD), PK profile, PD profile and preliminary efficacy.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02920697
Study type Interventional
Source Servier
Contact
Status Completed
Phase Phase 1
Start date March 2014
Completion date October 22, 2018

See also
  Status Clinical Trial Phase
Completed NCT02265731 - Study Evaluating Venetoclax in Subjects With Hematological Malignancies Phase 1/Phase 2
Recruiting NCT05442580 - CART-38 in Adult AML and MM Patients Phase 1
Terminated NCT04178902 - A Study of the Safety and Tolerability of ABBV-467 in Adult Participants With Relapsed/Refractory (R/R) Multiple Myeloma Phase 1
Recruiting NCT05908409 - A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies Phase 1/Phase 2
Active, not recruiting NCT04702425 - VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma) Phase 1
Completed NCT00710528 - Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies Phase 1
Completed NCT04721002 - Study to Evaluate t(11;14) Status and BCL2 Expression in Adult Participants With Multiple Myeloma (MM)
Active, not recruiting NCT02240537 - Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer Phase 1
Active, not recruiting NCT02203643 - Evaluation of the Safety and the Efficacy of Carfilzomib Combined With Cyclophosphamide and Dexamethasone (CCyd) or Lenalidomide and Dex (CRd) Followed by ASCT or 12 Cycles of Carf Combined With Dex and Len for Patients Eligible for ASCT With Newly Diagnosed Multiple Myeloma. Phase 2
Completed NCT02211014 - An Open-Label, Phase 1b Study of Acalabrutinib With and Without Dexamethasone in Subjects With Multiple Myeloma Phase 1
Recruiting NCT04649073 - Safety and Efficacy Study of OPC-415 in Patients With Relapsed and/or Refractory Multiple Myeloma Phase 1/Phase 2
Active, not recruiting NCT04123418 - A Study of WVT078 in Patients With Multiple Myeloma (MM) Phase 1
Recruiting NCT03018405 - A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications Phase 1/Phase 2
Terminated NCT01663766 - Phase I Study of Milatuzumab for Graft Versus Host Disease Phase 1
Completed NCT01919086 - Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma Phase 2
Withdrawn NCT05513612 - Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies Phase 1
Completed NCT01413568 - Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies Phase 1/Phase 2
Completed NCT00889798 - Tumor Registry of Lymphatic Neoplasia